Synthesis and antitumor activity of novel pyrazolo[1,5-a]pyrimidine derivatives by El-Enany, Mervat Mostafa et al.
European	Journal	of	Chemistry	2	(3)	(2011)	331‐336	
	
European	Journal	of	Chemistry	
ISSN	2153‐2249	(Print)	/	ISSN	2153‐2257	(Online)		2011	EURJCHEM	
DOI:10.5155/eurjchem.2.3.331‐336.319	
	
	
	
	
European	Journal	of	Chemistry	
Journal	homepage:	www.eurjchem.com	
	 	 	
Synthesis	and	antitumor	activity	of	novel	pyrazolo[1,5‐a]pyrimidine	derivatives
Mervat	Mostafa	El‐Enanya,	Mona	Monir	Kamelb,		
Omneya	Mahmoud	Khalilb	and	Hala	Bakr	El‐Nassanb,*	
a	Pharmacology	Chemistry	Department,	Faculty	of	Pharmaceutical	Science	and	Pharmaceutical	Industries,	Future	University,	Cairo,	11562,	Egypt**	
b	Organic	Chemistry	Department,	Faculty	of	Pharmacy,	Cairo	University,	Cairo,	11562,	Egypt	
*Corresponding	author	at:	Organic	Chemistry	Department,	Faculty	of	Pharmacy,	Cairo	University,	Cairo,	11562,	Egypt.	Tel.:	+00202.23632245;		
fax:	+00202.23635140.	E‐mail	address:	hala_bakr@hotmail.com	(H.B.	El‐Nassan).	
**	Sabbatical	leave	from	Cairo	University.	
	
	
	 	
	 	 	
ARTICLE	INFORMATION	 	 ABSTRACT	
Received:	14	November	2010	
Received	in	revised	form:	21	February	2011	
Accepted:	30	March	2011	
Online:	30	September	2011	
KEYWORDS	
	 A	 novel	 series	 of	 pyrazolo[1,5‐a]pyrimidine‐3‐carbonitriles	 substituted	 with	 7‐amino,
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synthesized	 compounds	 were	 tested	 in	 vitro	 on	 human	 colon	 tumor	 cell	 line	 (HCT116).
Compound	 14a	 displayed	 the	 highest	 activity	 among	 the	 tested	 compounds	 with	 IC50	 that
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1.	Introduction	
	
Cancer	 is	 defined	 as	 malignant	 growth	 of	 cells.	 Most	 tumors	
arise	 from	 a	 combination	 of	 genetic	 mutations	 in	 the	 cell.	 These	
genetic	changes	lead	to	activation	of	oncogenes	and	suppression	or	
deletion	 of	 tumor	 suppressor	 genes.	 As	 a	 result,	 there	 is	
unregulated	cell	proliferation	and	also	a	delay	in	programmed	cell	
death,	apoptosis	[1].	Most	of	the	clinically	used	antineoplastic	drugs	
aim	 to	suppress	 the	proliferative	process	 (e.g.:	DNA	replication	or	
chromosome	segregation)	[1].	
Pyrazolo[1,5‐a]pyrimidines	 are	 of	 considerable	 chemical	 and	
pharmacological	 importance	 as	 purine	 analogs	 and	 many	
derivatives	 of	 pyrazolo[1,5‐a]pyrimidines	 have	 been	 reported	 to	
exhibit	cytotoxic	activity	[2‐10].	Different	mechanisms	account	for	
the	 cytotoxic	 effect	 of	 this	 class	 of	 compounds,	 where	 they	 have	
been	reported	to	act	as	vascular	endothelial	growth	factor	receptor	
inhibitor	[2]	and	cyclin	dependent	kinase	inhibitors	[3,6‐8].	
Several	 7‐substituted	 aminopyrazolo[1,5‐a]pyrimidine	
derivatives	were	reported	to	have	antiproliferative	activity	against	
HCT116	and	other	cell	lines	(e.g.	compounds	1‐3)	[3,6,8]	(Figure	1).	
In	 the	 present	 study,	 several	 pyrazolo[1,5‐a]pyrimidine	
derivatives,	 bearing	 2‐methylsulphanyl	 group,	 3‐nitrile	 group	 and	
7‐amino	(6a,	6b,	7a‐d,	8	and	9)	or	7‐substituted	amino	group	(14a‐
c)	were	prepared.	Besides,	different	substitutions	were	introduced	
at	 position	 5	 (aromatic	 ring,	 amino	 group	 or	 carbonyl	 group)	
(Scheme	1	and	2).	
Meanwhile,	the	study	aimed	to	synthesize	7‐substituted	amino‐
5‐methylpyrazolo[1,5‐a]pyrimidine	 derivatives.	 Nevertheless,	 the	
product	obtained	using	two	different	reaction	conditions	was	the	7‐
methyl	derivative.	
	
2.	Experimental	
	
2.1.	Instrumentation	
Melting	points	were	determined	using	a	Griffin	apparatus	and	
were	uncorrected.	IR	spectra	were	recorded	on	Mattson	Genesis	II	
FT‐IR	 and	 values	were	 represented	 in	 cm‐1.	 1H	NMR	were	 carried	
out	on	Varian	Gemini	200 MHz spectrophotometer,	Microanalytical	
center,	 Cairo	 University,	 Cairo,	 Egypt,	 using	 TMS	 as	 an	 internal	
standard	and	chemical	shifts	were	recorded	in	ppm	on	δ	scale	and	
coupling	 constants	 (J)	 are	 given	 in	 Hz.	 The	 electron	 impact	 (EI)	
mass	 spectra	 were	 recorded	 on	 Shimadzu	 QP‐2010	 plus,	
Microanalytical	 center,	 Cairo	 University,	 Cairo,	 Egypt.	 Analytical	
thin	layer	chromatography	(TLC)	on	silica	gel	plates	containing	UV	
indicator	was	employed	routinely	to	follow	the	course	of	reactions	
and	to	check	the	purity	of	products.	All	reagents	and	solvents	were	
purified	 and	 dried	 by	 standard	 techniques.	 Elemental	
microanalyses	 were	 performed	 at	 Microanalytical	 Center,	 Cairo	
University,	Cairo,	Egypt,	and	were	within	±0.4%.	
	
2.2.	Synthesis	
	
2.2.1.	General	procedure	for	the	synthesis	of	7‐amino‐2‐methyl	
sulphanyl‐5‐(substituted	phenyl)‐4,5‐dihydropyrazolo	[1,5‐a]	
pyrimidine‐3,6‐dicarbonitriles	6a,b	and	7‐amino‐2‐methyl	
sulphanyl‐5‐(substituted	phenyl)pyrazolo[1,5‐a]pyrimidine‐3,6‐
dicarbonitriles	7a‐d	
	
A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐pyrazole‐4‐
carbonitrile	 (4)	 [11]	 (0.31	 g,	 0.002	 mol),	 the	 appropriate	
substituted	benzylidenemalononitrile	5a‐f	[12‐15]	(0.002	mol)	and	
triethylamine	(2	mL)	in	absolute	ethanol	(20	mL)	was	heated	under	
reflux	 for	 7	 h.	 The	 precipitate	 formed	 was	 filtered,	 dried	 and	
crystallized	from	acetic	acid.	
7‐Amino‐5‐(2‐chlorophenyl)‐2‐methylsulphanyl‐4,5‐dihydro	
pyrazolo[1,5‐a]pyrimidine‐3,6‐dicarbonitrile	 (6a):	 Yield:	 33%.	M.p.:	
246‐247	oC.	FT‐IR	(cm‐1):	3453,	3307,	3236	(NH/NH2),	2228,	2192	
(CN).	1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	2.6	(s,	3H,	SCH3),	5.7	(d,		
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Figure	1.	Examples	of	7‐substituted	aminopyrazolo[1,5‐a]pyrimidines	with	antiproliferative	activity.	
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Scheme	1	
	
	
1H,	H5,	 J=2	Hz),	7.3	(s,	1H,	NH,	D2O	exchangeable),	7.4‐7.5	(m,	4H,	
Ar‐H),	 9.2	 (s,	 2H,	 NH2,	 D2O	 exchangeable).	 Anal.	 Calcd.	 for	
C15H11ClN6S:	C,	52.55;	H,	3.23;	N,	24.51.	Found:	C,	52.62;	H,	3.44;	N,	
24.27%.	
7‐Amino‐5‐(2‐methoxyphenyl)‐2‐methylsulphanyl‐4,5‐dihydro	
pyrazolo[1,5‐a]pyrimidine‐3,6‐dicarbonitrile	 (6b):	 Yield:	 48%.	M.p.:	
244‐245	oC.	FT‐IR	(cm‐1):	3425,	3277,	3219	(NH/NH2),	2218,	2189	
(CN).	1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	2.6	(s,	3H,	SCH3),	3.7	(s,	
3H,	OCH3),	5.4	(s,	1H,	H5),	7.2	(s,	1H,	NH,	D2O	exchangeable),	6.9‐7.3	
(m,	 4H,	 Ar‐H),	 9.0	 (s,	 2H,	NH2,	 D2O	 exchangeable).	MS	 (m/z	 (%)):	
338	 [M+,	 1.12%].	 Anal.	 Calcd.	 for	 C16H14N6OS:	 C,	 56.79;	H,	 4.17;	N,	
24.83.	Found:	C,	56.50;	H,	3.84;	N,	24.97%.	
7‐Amino‐5‐(2‐hydroxyphenyl)‐2‐methylsulphanylpyrazolo[1,5‐a]	
pyrimidine‐3,6‐dicarbonitrile	(7a):	Yield:	22%.	M.p.:	224‐225	oC.	FT‐
IR	(cm‐1):	3436,	3344	(NH2),	2200	(CN).	1H	NMR	(200	MHz,	DMSO‐
d6,	δ	ppm):	2.7	(s,	3H,	SCH3),	7.1‐8.2	(m,	4H,	Ar‐H),	8.9	(s,	2H,	NH2,	
D2O	exchangeable),	9.3	(s,	1H,	OH,	D2O	exchangeable).	Anal.	Calcd.	
for	C15H10N6OS:	C,	55.89;	H,	3.12;	N,	26.07.	Found:	C,	56.02;	H,	3.59;	
N,	26.23%.	
7‐Amino‐2‐methylsulphanyl‐5‐(3‐nitrophenyl)pyrazolo[1,5‐a]	
pyrimidine‐3,6‐dicarbonitrile	(7b):	Yield:	44%.	M.p.:	287‐288	oC.	FT‐
IR	(cm‐1):	3308,	3273	(NH2),	2214,	2131	(CN),	1528,	1345	(NO2).	1H	
NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	2.7	(s,	3H,	SCH3),	7.8	(t,	1H,	J=8	
Hz,	Ar‐H),	8.3	(d,	1H,	 J=7.8	Hz,	Ar‐H),	8.4	(d,	1H,	J=8	Hz,	Ar‐H),	8.6	
(s,	1H,	Ar‐H),	9.4	(br	s,	2H,	NH2,	D2O	exchangeable).	Anal.	Calcd.	for	
C15H9N7O2S:	C,	51.27;	H,	2.58;	N,	27.90.	Found:	C,	51.71;	H,	2.30;	N,	
27.80%.	
	
7‐Amino‐5‐(4‐chlorophenyl)‐2‐methylsulphanylpyrazolo[1,5‐a]	
pyrimidine‐3,6‐dicarbonitrile	(7c):	Yield:	45%.	M.p.:	273‐274	oC.	FT‐
IR	(cm‐1):	3439,	3297	(NH2),	2222	(CN).	1H	NMR	(200	MHz,	DMSO‐
d6,	δ	ppm):	2.7	(s,	3H,	SCH3),	7.6	(d,	2H,	J=7.6	Hz,	Ar‐H),	7.8	(d,	2H,	
J=7.6	 Hz,	 Ar‐H),	 9.3	 (br	 s,	 2H,	 NH2,	 D2O	 exchangeable).	 MS	 (m/z	
(%)):	 342	 [(M+2)+,	 38.96%],	 340	 [M+,	 100%].	 Anal.	 Calcd.	 for	
C15H9ClN6S:	C,	52.86;	H,	2.66;	N,	24.65.	Found:	C,	52.70;	H,	2.30;	N,	
24.86.	
7‐Amino‐5‐(4‐dimethylaminophenyl)‐2‐methylsulphanylpyrazolo	
[1,5‐a]pyrimidine‐3,6‐dicarbonitrile	(7d):	Yield:	32%.	M.p.:	280‐281	
oC.	FT‐IR	(cm‐1):	3449,	3370	(NH2),	2209	(CN).	 1H	NMR	(200	MHz,	
DMSO‐d6,	δ	ppm):	2.7	(s,	3H,	SCH3),	3.0	(s,	6H,	‐N(CH3)2),	6.7	(d,	2H,	
J=8.8	Hz,	Ar‐H),	7.8	(d,	2H,	 J=9.2	Hz,	Ar‐H),	9.0	(br	s,	2H,	NH2,	D2O	
exchangeable).	 Anal.	 Calcd.	 for	 C17H15N7S:	 C,	 58.43;	 H,	 4.32;	 N,	
28.05.	Found:	C,	58.73;	H,	4.64;	N,	28.30%.	
	
2.2.2.	5,7‐Diamino‐2‐methylsulphanylpyrazolo[1,5‐a]	
pyrimidine‐3‐carbonitrile	(8)	
	
A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐pyrazole‐4‐
carbonitrile	 (4)	 (0.77	 g,	 0.005	 mol),	 malononitrile	 (0.33	 g,	 0.005	
mol)	 and	 triethylamine	 (2	 mL)	 in	 absolute	 ethanol	 (30	 mL)	 was	
heated	under	reflux	 for	10	h.	The	precipitate	 formed	was	 filtered,	
dried	 and	 crystallized	 from	 acetic	 acid.	 Yield:	 26%.	M.p.:	 254‐255	
oC.	FT‐IR	(cm‐1):	3479,	3431,	3373,	3317	(NH2),	2203	(CN).	1H	NMR	
(200	MHz,	DMSO‐d6,	δ	ppm):	2.6	(s,	3H,	SCH3),	5.3	(s,	1H,	H6),	6.7	(s,	
2H,	 NH2,	 D2O	 exchangeable),	 7.3	 (s,	 2H,	 NH2,	 D2O	 exchangeable).	
Anal.	Calcd.	for	C8H8N6S:	C,	43.62;	H,	3.66;	N,	38.15.	Found:	C,	43.99;	
H,	3.55;	N,	38.60%.	
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Scheme	2
	
	
2.2.3.	7‐Amino‐2‐methylsulphanyl‐5‐oxo‐4,5‐dihydropyrazolo	
[1,5‐a]pyrimidine‐3‐carbonitrile	(9)	
	
A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐pyrazole‐4‐
carbonitrile	(4)	(2.31	g,	0.015	mol)	and	ethyl	cyanoacetate	(1.69	g,	
1.70	mL,	0.015	mol)	was	heated	at	160	oC	in	an	oil	bath	for	2	h.	The	
solid	 formed	 was	 triturated	 with	 ethanol	 (10	mL),	 filtered,	 dried	
and	crystallized	from	DMF.	Yield:	93%.	M.p.:	>300	oC.	FT‐IR	(cm‐1):	
3433,	 3319	 (NH/NH2),	 2220	 (CN),	 1650	 (CO).	 1H	NMR	 (200	MHz,	
DMSO‐d6,	δ	ppm):	2.6	(s,	3H,	SCH3),	5.2	(d,	1H,	H6,	J=2.2	Hz),	7.6	(s,	
2H,	NH2,	D2O	exchangeable),	11.9	(br	s,	1H,	NH,	D2O	exchangeable).	
Anal.	 Calcd.	 for	 C8H7N5OS:	 C,	 43.43;	 H,	 3.18;	 N,	 31.65.	 Found:	 C,	
43.01;	H,	3.36;	N,	31.22%.	
	
2.2.4.	2‐Methylsulphanyl‐5‐phenyl‐7‐oxo‐4,7‐dihydropyrazolo	
[1,5‐a]pyrimidine‐3‐carbonitrile	(10)	
	
A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐pyrazole‐4‐
carbonitrile	(4)	(2.31	g,	0.015	mol)	and	ethyl	benzoylacetate	(2.88	
g,	2.60	mL,	0.015	mol)	was	heated	at	160	oC	in	an	oil	bath	for	2	h.	
The	 solid	 formed	 was	 triturated	 with	 ethanol	 (10	 mL),	 filtered,	
dried	 and	 crystallized	 from	acetic	 acid.	 Yield:	 67%.	M.p.:	 268‐269	
oC.	 FT‐IR	 (cm‐1):	 3466	 (NH),	 2222	 (CN),	 1718	 (CO).	 1H	NMR	 (200	
MHz,	 DMSO‐d6,	 δ	 ppm):	 2.6	 (s,	 3H,	 SCH3),	 6.2	 (s,	 1H,	 NH,	 D2O	
exchangeable),	 7.5‐7.8	 (m,	 6H,	 Ar‐H+	 H6).	 Anal.	 Calcd.	 for	
C14H10N4OS:	C,	59.56;	H,	3.57;	N,	19.84.	Found:	C,	59.97;	H,	3.57;	N,	
20.16%.	
	
2.2.5.	7‐Methyl‐2‐methylsulphanyl‐5‐oxo‐4,5‐dihydropyrazolo	
[1,5‐a]pyrimidine‐3‐carbonitrile	(11)	
	
Method	 A:	 A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐
pyrazole‐4‐carbonitrile	 (4)	 (2.31	 g,	 0.015	 mol)	 and	 ethyl	
acetoacetate	 (1.95	g,	1.90	mL,	0.015	mol)	was	heated	at	170	 oC	 in	
an	 oil	 bath	 for	 2	h.	 The	 solid	 product	was	 triturated	with	 ethanol	
(10	mL),	filtered,	dried	and	crystallized	from	acetic	acid.	
Method	 B:	 A	 mixture	 of	 5‐amino‐3‐methylsulphanyl‐1H‐
pyrazole‐4‐carbonitrile	 (4)	 (2.31	 g,	 0.015	 mol)	 and	 ethyl	
acetoacetate	(1.95	g,	1.90	mL,	0.015	mol)	 in	glacial	acetic	acid	(50	
mL)	 was	 heated	 under	 reflux	 for	 15	 h.	 The	 solid	 formed	 was	
filtered,	dried	and	crystallized	from	acetic	acid.	
Yield:	90%	(Method	A),	77%	(Method	B).	M.p.:	300‐301	oC	[16].	
FT‐IR	(cm‐1):	3470	(NH),	2225	(CN),	1661	(CO).	1H	NMR	(200	MHz,	
DMSO‐d6,	δ	ppm):	2.2	(s,	3H,	CH3),	2.6	(s,	3H,	SCH3),	5.8	(s,	1H,	H6),	
13.2	(s,	1H,	NH,	D2O	exchangeable).	
	
2.2.6.	General	procedure	for	the	synthesis	of	pyrazolo[1,5‐a]	
pyrimidines	12	and	13	
	
A	mixture	 of	 pyrazolo[1,5‐a]pyrimidine	 derivatives	10	 or	 11	
(0.004	 mol)	 and	 phosphorus	 oxychloride	 (20	 mL)	 was	 heated	
under	reflux	 for	7	h.	The	reaction	mixture	was	cooled	and	poured	
gradually	 onto	 crushed	 ice.	 The	 resulting	 product	 was	 filtered,	
dried,	and	crystallized	from	ethanol.	
7‐Chloro‐2‐methylsulphanyl‐5‐phenylpyrazolo[1,5‐a]	pyrimidine‐
3‐carbonitrile	 (12):	 Yield:	 73%.	 M.p.:	 196‐197	 oC.	 FT‐IR	 (cm‐1):	
2220	(CN).	1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	2.7	(s,	3H,	SCH3),	
7.5‐8.2	(m,	6H,	Ar‐H	+	H6).	Anal.	Calcd.	for	C14H9ClN4S:	C,	55.90;	H,	
3.01;	N,	18.62.	Found:	C,	56.00;	H,	3.23;	N,	18.20%.	
5‐Chloro‐7‐methyl‐2‐methylsulphanylpyrazolo[1,5‐a]	
pyrimidine‐3‐carbonitrile	 (13):	Yield:	71%.	M.p.:	220‐221	oC.	FT‐IR	
(cm‐1):	2223	(CN).	1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	2.6	(s,	3H,	
CH3),	2.7	(s,	3H,	SCH3),	7.5	(s,	1H,	H6).	Anal.	Calcd.	for	C9H7ClN4S:	C,	
45.28;	H,	2.95;	N,	23.47.	Found:	C,	45.65;	H,	2.96;	N,	23.45%.	
	
2.2.7.	General	procedure	for	the	synthesis	of	2‐methylsulphanyl‐
5‐phenyl‐7‐(substituted	amino)pyrazolo[1,5‐a]pyrimidine‐3‐
carbonitriles	14a‐c	
334	 El‐Enany	et	al.	/	European	Journal	of	Chemistry	2	(3)	(2011)	331‐336	
	
A	mixture	 of	 7‐chloropyrazolo[1,5‐a]pyrimidine	 derivative	12	
(0.60	g,	0.002	mol),	the	appropriate	primary	amine	(0.002	mol)	and	
triethylamine	 (0.50	 mL)	 in	 absolute	 ethanol	 (20	 mL)	 was	 heated	
under	reflux	for	9	h.	The	reaction	mixture	was	concentrated	under	
reduced	pressure,	 and	 the	solid	 formed	upon	 cooling	was	 filtered,	
dried	and	crystallized	from	the	suitable	solvent.	
7‐Cyclohexylamino‐2‐methylsulphanyl‐5‐phenylpyrazolo[1,5‐a]	
pyrimidine‐3‐carbonitrile	 (14a):	 (Crystallized	 from	 ethanol).	 Yield:	
60%.	M.p.:	194‐195	oC.	FT‐IR	(cm‐1):	3383	(NH),	2213	(CN).	1H	NMR	
(200	MHz,	DMSO‐d6,	 δ	 ppm):	 1.2‐1.9	 (m,	 11H,	 aliphatic‐H),	 2.7	 (s,	
3H,	SCH3),	7.0	(s,	1H,	H6),	7.5‐8.2	(m,	5H,	Ar‐H),	7.8	(s,	1H,	NH,	D2O	
exchangeable).	 Anal.	 Calcd.	 for	 C20H21N5S:	 C,	 66.08;	 H,	 5.82;	 N,	
19.26.	Found:	C,	66.20;	H,	5.60;	N,	19.39%.	
7‐Anilino‐2‐methylsulphanyl‐5‐phenylpyrazolo[1,5‐a]pyrimidine‐
3‐carbonitrile	 (14b):	 (Crystallized	 from	 acetic	 acid).	 Yield:	 44%.	
M.p.:	254‐255	oC.	FT‐IR	(cm‐1):	3349	(NH),	2211	(CN).	1H	NMR	(200	
MHz,	 DMSO‐d6,	 δ	 ppm):	 2.8	 (s,	 3H,	 SCH3),	 6.7‐8.3	 (m,	 11H,	 Ar‐H),	
10.3	 (s,	 1H,	 NH,	 D2O	 exchangeable).	 Anal.	 Calcd.	 for	 C20H15N5S:	 C,	
67.20;	H,	4.22;	N,	19.59.	Found:	C,	67.05;	H,	4.12;	N,	19.84%.	
7‐(4‐Methoxyanilino)‐2‐methylsulphanyl‐5‐phenylpyrazolo[1,5‐
a]pyrimidine‐3‐carbonitrile	 (14c):	 (Crystallized	 from	 ethanol).	
Yield:	70%.	M.p.:	192‐193	 oC.	FT‐IR	 (cm‐1):	3305	 (NH),	2211	 (CN).	
1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	2.8	(s,	3H,	SCH3),	3.8	(s,	3H,	
OCH3),	 6.5‐7.9	 (m,	 10H,	 Ar‐H),	 8.2	 (s,	 1H,	 NH,	 D2O	 exchangeable).	
Anal.	 Calcd.	 for	 C21H17N5OS:	 C,	 65.09;	 H,	 4.42;	 N,	 18.07.	 Found:	 C,	
65.00;	H,	4.23;	N,	17.77%.	
	
2.2.8.	General	procedure	for	the	synthesis	of	7‐methyl‐2‐
methylsulphanyl‐5‐(substituted	amino)pyrazolo[1,5‐a]	
pyrimidine‐3‐carbonitriles	15a‐d	
	
A	mixture	 of	 5‐chloropyrazolo[1,5‐a]pyrimidine	 derivative	13	
(0.48	g,	0.002	mol),	the	appropriate	primary	amine	(0.002	mol)	and	
triethylamine	 (0.50	 mL)	 in	 absolute	 ethanol	 (20	 mL)	 was	 heated	
under	reflux	for	11	h.	The	reaction	mixture	was	concentrated	under	
reduced	 pressure,	 and	 the	 product	 formed	 upon	 cooling	 was	
filtered,	dried	and	crystallized	from	ethanol.	
5‐Cyclohexylamino‐7‐methyl‐2‐methylsulphanylpyrazolo[1,5‐a]	
pyrimidine‐3‐carbonitrile	(15a):	Yield:	91%.	M.p.:	180‐181	oC.	FT‐IR	
(cm‐1):	3378	(NH),	2211	(CN).	1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	
1.2‐1.9	(m,	11H,	aliphatic‐H),	2.4	(s,	3H,	CH3),	2.7	(s,	3H,	SCH3),	6.4	
(s,	 1H,	H6),	 7.7	 (br	 s,	 1H,	 NH,	 D2O	 exchangeable).	 Anal.	 Calcd.	 for	
C15H19N5S:	 C,	 59.77;	H,	 6.35;	N,	 23.23.	 Found:	 C,	 59.55;	H,	 6.31;	N,	
22.92%.	
5‐Anilino‐7‐methyl‐2‐methylsulphanylpyrazolo[1,5‐a]pyrimi‐
dine‐3‐carbonitrile	 (15b):	Yield:	77%.	M.p.:	209‐210	oC.	FT‐IR	(cm‐
1):	3215	(NH),	2230	(CN).	1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	2.3	
(s,	3H,	CH3),	2.7	(s,	3H,	SCH3),	6.2	(s,	1H,	H6),	7.1‐7.5	(m,	5H,	Ar‐H),	
10.0	 (s,	 1H,	 NH,	 D2O	 exchangeable).	 Anal.	 Calcd/	 for	 C15H13N5S:	 C,	
60.99;	H,	4.43;	N,	23.71.	Found:	C,	60.86;	H,	4.60;	N,	23.45%.	
5‐(4‐Methoxyanilino)‐7‐methyl‐2‐methylsulphanylpyrazolo[1,5‐
a]pyrimidine‐3‐carbonitrile	(15c):	Yield:	59%.	M.p.:	168‐169	oC.	FT‐
IR	 (cm‐1):	 3362	 (NH),	 2217	 (CN).	 1H	 NMR	 (200	MHz,	 DMSO‐d6,	 δ	
ppm):	2.3	(s,	3H,	CH3),	2.7	(s,	3H,	SCH3),	3.8	(s,	3H,	OCH3),	6.0	(s,	1H,	
H6),	7.0	 (d,	2H,	 J=8.7	Hz,	Ar‐H),	 7.3	 (d,	2H,	 J=8.7	Hz,	Ar‐H),	9.9	 (s,	
1H,	NH,	 D2O	 exchangeable).	MS	 (m/z	 (%)):	 325	 [M+,	 100%].	Anal.	
Calcd.	for	C16H15N5OS:	C,	59.06;	H,	4.64;	N,	21.52.	Found:	C,	59.39;	H,	
5.10;	N,	21.11%.	
5‐(2‐Methylanilino)‐7‐methyl‐2‐methylsulphanylpyrazolo[1,5‐a]	
pyrimidine‐3‐carbonitrile	(15d):	Yield:	53%.	M.p.:	192‐193	oC.	FT‐IR	
(cm‐1):	3368	(NH),	2214	(CN).	1H	NMR	(200	MHz,	DMSO‐d6,	δ	ppm):	
2.2	 (s,	 3H,	 CH3C6H4),	 2.3	 (s,	 3H,	 CH3),	 2.7	 (s,	 3H,	 SCH3),	 5.7	 (s,	 1H,	
H6),	7.3‐7.4	(m,	4H,	Ar‐H),	9.9	(s,	1H,	NH,	D2O	exchangeable).	Anal.	
Calcd.	for	C16H15N5S:	C,	62.11;	H,	4.88;	N,	22.63.	Found:	C,	62.40;	H,	
4.55;	N,	22.29%.	
	
2.3.	Biological	testing	
	
2.3.1.	Materials	and	methods	
	
The	human	colon	 tumor	 cell	 line	 (HCT116)	was	obtained	as	 a	
gift	 from	 National	 Cancer	 Institute	 NCI,	 Maryland	 MD,	 USA.	 All	
chemicals	and	solvents	were	purchased	from	Sigma–Aldrich.	
	
	
2.3.2.	Measurement	of	potential	cytotoxicity	
	
The	 cytotoxic	 activity	 of	 some	 of	 the	 newly	 synthesized	
compounds	 was	 tested	 in	 vitro	 on	 human	 colon	 tumor	 cell	 line	
(HCT116)	 using	 Sulforhodamine‐B	 stain	 (SRB)	 assay	 according	 to	
the	method	of	Skehan	et	al.	 [17].	Cells	were	plated	in	96‐multiwell	
plate	 (104	 cells/well)	 for	 24	 h	 before	 treatment	 with	 the	 tested	
compounds	to	allow	attachment	of	the	cells	to	the	wall	of	the	plate.	
The	 tested	 compounds	 were	 dissolved	 in	 DMSO	 and	 diluted	 with	
saline	 to	 the	 appropriate	 volume.	 Different	 concentrations	 of	 the	
tested	compound	(0,	1,	2.5,	5	and	10	μg/mL)	were	added	to	the	cell	
monolayer.	 Triplicate	 wells	 prepared	 for	 each	 individual	 dose.	
Monolayer	cells	were	incubated	with	the	tested	compound	for	48	h	
at	37	oC	in	atmosphere	of	5%	CO2.	After	48	h,	cells	were	fixed	with	
trichloroacetic	acid,	washed	with	water	and	stained	for	30	min	with	
0.4%	(w:v)	 Sulforhodamine‐B	 stain	dissolved	with	1%	acetic	 acid.	
Excess	stain	was	removed	by	four	washes	with	1%	acetic	acid	and	
attached	 stain	 was	 recovered	 with	 Tris	 EDTA	 buffer.	 Colour	
intensity	 was	 measured	 in	 ELISA	 reader.	 The	 relation	 between	
surviving	 fraction	 and	 compound	 concentration	 was	 plotted	 and	
IC50	(the	concentration	required	for	50%	inhibition	of	cell	viability)	
was	calculated	for	each	compound	and	results	are	given	in	Table	1.	
Figure	2	 represents	 IC50	in	 μM	of	 the	 synthesized	 compounds	 and	
doxorubicin	against	human	colon	tumor	cell	line	(HCT116)	
	
Table	 1.	 Results	 of	 in	 vitro	 cytotoxic	 activity	 of	 some	 of	 the	 synthesized	
compounds	on	human	colon	tumor	cell	line	(HCT116).	
Compound	no. IC50	in	μM*
Doxorubicin 0.0069	
7b 0.0062	
7c 0.0375	
8 0.0433	
9 0.0814	
14a 0.0020	
14b 0.0113	
14c	 0.0238	
15c 0.0077	
15d	 0.0598	
*The	values	given	are	means	of	three	experiments.	
	
	
	
Figure	2. IC50 in	μM	of	 the	synthesized	compounds	and	doxorubicin	against	
human	colon	tumor	cell	line	(HCT116).	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
The	synthesis	of	the	target	compounds	is	outlined	in	Schemes	1	
and	 2.	 The	 starting	 compound,	 5‐amino‐3‐methylsulphanyl‐1H‐
pyrazole‐4‐carbonitrile	 (4)	 [11]	was	 reacted	with	 the	appropriate	
substituted	 benzylidenemalononitrile	 5a‐f	 [12‐15]	 to	 afford	 7‐
amino‐2‐methylsulphanyl‐5‐(substituted	 phenyl)‐4,5‐dihydropyra‐
zolo[1,5‐a]pyrimidine‐3,6‐dicarbonitriles	 6a,b	 or	 7‐amino‐2‐
methylsulphanyl‐5‐(substituted	phenyl)pyrazolo[1,5‐a]pyrimidine‐
3,6‐dicarbonitriles	7a‐d.	
The	 reaction	 of	 the	 pyrazole	 derivative	 4	 with	 substituted	
benzylidenemalononitriles	5a‐f	may	proceed	via	initial	nucleophilic	
attack	 by	 the	 exocyclic	 amino	 group	 of	 compound	 4	 on	 the	
activated	 double	 bond	 in	 5a‐f	 to	 form	 a	 Micheal	 adduct.	
Intramolecular	cyclization	of	the	latter	may	result	in	the	formation	
of	 the	 dihydro	 derivative	 6	 which	 may	 then	 aromatize	 into	 7	
(Scheme	3).	
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Scheme	3	
	
	
Trials	to	oxidize	6a,b	into	7	(R=2‐Cl,	2‐CH3O)	via	the	use	of	two	
molar	 equivalents	 of	 benzylidenemalononitriles	 5a,b	 or	 by	
increasing	the	time	of	the	reaction	(up	to	15	h)	were	unsuccessful.	
Compound	4	was	 also	 reacted	with	malononitrile	 to	 give	 5,7‐
diaminopyrazolo[1,5‐a]pyrimidine	 8.	 1H	 NMR	 spectrum	 of	
compound	8	revealed	the	presence	of	a	singlet	signal	at	δ	5.3	ppm	
corresponding	to	H6	and	two	exchangeable	singlet	signals	at	δ	6.7	
and	δ	7.3	ppm	corresponding	to	protons	of	the	two	NH2	groups	at	
positions	5	and	7,	respectively.	
Furthermore,	1H‐pyrazole	derivative	4	was	reacted	with	ethyl	
cyanoacetate,	 ethyl	 benzoylacetate	 and	 ethyl	 acetoacetate	 to	 give	
one	 of	 two	possible	 products;	 the	 5‐oxopyrazolo[1,5‐a]pyrimidine	
or	the	7‐oxo	isomer	(Scheme	4).	The	assignment	of	the	product	as	
5‐oxo	 or	 7‐oxopyrazolo[1,5‐a]pyrimidine	 depends	 on	 1H	 NMR	
study.	
	
 
	
Scheme	4	
	
The	reaction	of	compound	4	with	ethyl	cyanoacetate	and	ethyl	
acetoacetate	 afforded	 5‐oxopyrazolo[1,5‐a]pyrimidine	 derivatives	
9	 and	11,	 respectively.	Both	 compounds	showed	an	exchangeable	
singlet	 signal	 at	 δ	 11.9	 ppm	 and	 δ	 13.2	 ppm,	 respectively,	
corresponding	to	NH	proton	due	to	tautomerism	with	the	adjacent	
carbonyl	 group.	 The	 7‐oxo	 isomer,	 lacking	 such	 tautomerism,	
should	give	that	signal	at	δ	5‐7	ppm.	
On	 the	 other	 hand,	 the	 reaction	 of	 compound	 4	 with	 ethyl	
benzoylacetate	 afforded	 7‐oxopyrazolo[1,5‐a]pyrimidine	 10.	
Herein,	 1H	 NMR	 of	 compound	 10	 revealed	 the	 presence	 of	 an	
exchangeable	 singlet	 signal	 at	 δ	 6.2	 ppm	 corresponding	 to	 NH	
proton.	
Chlorination	of	compounds	10	and	11	with	POCl3	 followed	by	
nucleophilic	 substitution	 with	 primary	 amines	 afforded	 7‐
(substituted	 amino)	 and	 5‐(substituted	 amino)pyrazolo[1,5‐
a]pyrimidine	derivatives	14a‐c	and	15a‐d,	respectively.	
	
3.2.	In	vitro	anticancer	screening	
	
Some	of	the	newly	synthesized	compounds	were	evaluated	for	
their	in	vitro	cytotoxic	activity	against	human	colon	tumor	cell	line,	
HCT116.	Doxorubicin	which	is	one	of	the	most	effective	anticancer	
agents	was	used	as	the	reference	drug	in	this	study.	
The	 response	 parameter	 calculated	was	 the	 IC50	 value,	which	
corresponds	 to	 the	 concentration	 required	 for	 50%	 inhibition	 of	
cell	viability.	The	IC50	in	μM	of	the	tested	compounds	compared	to	
the	 reference	 drug	 are	 shown	 in	 Table	 1	 and	 represented	
graphically	in	Figure	2.	
From	 the	 results	 in	 Table	 1,	 it	 was	 found	 that	 all	 the	 tested	
compounds	exhibited	good	antitumor	activity	against	HCT116	with	
IC50	between	0.0020	and	0.0814	μM.	
Two	of	the	tested	compounds	(7b	and	14a)	showed	antitumor	
activity	superior	to	doxorubicin	with	IC50	that	equals	to	0.0069	and	
0.0020	μM,	respectively.	
The	 best	 results	 were	 obtained	 by	 5‐phenyl‐7‐(substituted	
amino)pyrazolo[1,5‐a]pyrimidine	 derivatives	 14a‐c,	 and	 the	
highest	 activity	 was	 obtained	 by	 7‐cyclohexylamino‐2‐
methylsulphanyl‐5‐phenylpyrazolo[1,5‐a]pyrimidine‐3‐
carbonitrile	(14a).	
	
4.	Conclusion	
	
In	 summary,	 a	 novel	 series	 of	 pyrazolo[1,5‐a]pyrimidine‐3‐
carbonitriles	 substituted	with	 7‐amino	 (6‐9),	 7‐substituted	 amino	
(14a‐c)	and	5‐substituted	amino	(15a‐d)	was	synthesized.	Some	of	
the	newly	 synthesized	 compounds	were	 tested	 in	vitro	 on	 human	
colon	 tumor	 cell	 line	 (HCT116).	 Most	 of	 the	 tested	 compounds	
exhibited	good	antitumor	activity,	especially	compound	14a	which	
displayed	 the	 highest	 activity	 among	 the	 tested	 compounds	 with	
IC50	that	equals	to	0.0020	μM.		
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